-
08:35:25 PM
Sign in with email
Forgot your password?
Register with email
Account Verification

ANIP Stock News

11/22/21 6:50 AM
Nasdaq : ANIP
acquisitionlow float
ANI Pharmaceuticals Completes Acquisition of Novitium Pharma, Significantly Enhancing R&D Capabilities and Scale of Generics and CDMO Businesses
ANI Pharmaceuticals, Inc. today announced that it has completed the previously announced acquisition of Novitium Pharma, a privately held, New Jersey- based pharmaceutical company with development, manufacturing, and commercialization capabilities. “ANI is thrilled to welcome the expertise and leadership of Novitium’ s founders, Samy Shanmugam, Chad...
RHEA-AI
positive
11/22/21 6:40 AM
Nasdaq : ANIP
conferenceslow float
ANI Pharmaceuticals to Present at the Piper Sandler 33rd Annual Healthcare Conference 2021
ANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows:. ANI Pharmaceuticals will be participating in 1 x1 meetings. ANI Pharmaceuticals is a diversified bio-pharmaceutical company...
RHEA-AI
neutral
11/11/21 6:50 AM
Nasdaq : ANIP
acquisitionlow float
ANI Pharmaceuticals Receives Clearance from U.S. Federal Trade Commission for the Acquisition of Novitium Pharma
ANI Pharmaceuticals, Inc. today announced that the U.S. Federal Trade Commission has accepted the proposed consent order in connection with ANI's definitive agreement to acquire Novitium Pharma. The divestitures required by the FTC of development rights to one generic drug and assets with respect to another generic drug are immaterial to the Company’ s...
RHEA-AI
neutral
11/08/21 4:05 PM
Nasdaq : ANIP
offeringlow float
ANI Pharmaceuticals, Inc. Announces Closing of $75 Million Public Offering of Common Stock
ANI Pharmaceuticals, Inc. today announced the closing of its previously announced underwritten public offering. The securities described above were offered by ANI pursuant to a shelf registration statement on Form S-3, which was filed by the Company with the Securities and Exchange Commission on July 9, 2020 and was declared effective by the SEC on July 17,...
RHEA-AI
neutral
11/03/21 10:54 PM
Nasdaq : ANIP
offeringlow float
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
ANI Pharmaceuticals, Inc. today announced the pricing of an underwritten public offering of 1,500,000 shares of its common stock at a public offering price of $50.00 per share. The securities described above are being offered by ANI pursuant to a shelf registration statement on Form S-3 which was initially filed by the Company with the Securities and...
RHEA-AI
neutral
11/01/21 6:30 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces FDA Approval of Purified Cortrophin™ Gel for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis and Nephrotic Syndrome
ANI Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved the Company’ s supplemental New Drug Application for Purified Cortrophin™ Gel for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis, in addition to excess urinary protein due...
RHEA-AI
neutral
09/20/21 4:30 PM
Nasdaq : ANIP
conferenceslow float
ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021
ANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows:. About ANI ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and...
RHEA-AI
neutral